Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Suzuki, Hiroyuki ^a   Fukuhara, Mitsuro ^a   Yamaura, Takumi ^a   Mutoh, Satoshi ^a   Okabe, Naoyuki ^a   Yaginuma, Hiroshi ^a   Hasegawa, Takeo ^a   Yonechi, Atsushi ^a   Osugi, Jun ^a   Hoshino, Mika ^a   Kimura, Takashi ^a   Higuchi, Mitsunori ^a   Shio, Yutaka ^a   Ise, Kazuya ^a   Takeda, Kazuyoshi ^b   Gotoh, Mitsukazu ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

Cancer vaccine; Multiple peptides; Non small cell lung cancer; Prognosis

Indexed keywords

ANGIOGENESIS INHIBITOR; CANCER TESTIS ANTIGEN; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FREUND ADJUVANT; GAMMA INTERFERON; HLA A24 ANTIGEN; LYMPHOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN 6 COMPLEX LOCUS K; MONTANIDE ISA 51; PEPTIDE VACCINE; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; SUBUNIT VACCINE; TUMOR ANTIGEN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONSTIPATION; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE REACTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MALE; NAUSEA AND VOMITING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRURITUS; SIDE EFFECT; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; FEASIBILITY STUDY; IMMUNITY; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; LUNG NEOPLASMS; MIDDLE AGED; SURVIVAL;

AGED; ANGIOGENESIS INHIBITORS; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNITY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 84875930616     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-97     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012, 307:2418-2429.
3. Min JH, Lee HY, Lim H, Ahn MJ, Park K, Chung MP, Lee KS. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother Pharmacol 2011, 68:1099-1109. 10.1007/s00280-011-1737-2, 21913033.
4. Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 2009, 10:28-35. 10.3816/CLC.2009.n.004, 19289369.
5. Vansteenkiste J, Zielinski M, Linder A, Dahabre J, Esteban E, Malinowski W, Jassem J, Passlick B, Lehmann F, Brichard VG. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2007, 25:s7554.
6. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis P, MacNeil M, Palmer M. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005, 23:6674-6681. 10.1200/JCO.2005.13.011, 16170175.
7. Bae J, Smith R, Daley J, Mimura N, Tai YT, Anderson KC, Munshi NC. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: A potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res 2012, 18:4850-4860. 10.1158/1078-0432.CCR-11-2776, 22753586.
8. Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, Tsunoda T, Kawaguchi Y, Nakamura Y, Fujii H. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009, 100:1502-1509. 10.1111/j.1349-7006.2009.01200.x, 19459850.
9. Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 2007, 67:11601-11611. 10.1158/0008-5472.CAN-07-3243, 18089789.
10. Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen HLA-A24-restricted epitope-peptides derived from gene products up-regulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 2007, 98:1803-1808.
11. Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res 2006, 12:5841-5849. 10.1158/1078-0432.CCR-06-0750, 17020992.
12. Hayama S, Daigo Y, Kato T, Ishikawa N, Yamabuki T, Miyamoto M, Ito T, Tsuchiya E, Kondo S, Nakamura Y. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res 2006, 66:10339-10348. 10.1158/0008-5472.CAN-06-2137, 17079454.
13. Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res 2005, 65:4939-4946. 10.1158/0008-5472.CAN-04-3759, 15930316.
14. Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, Noguchi T, Fujii H, Okinaka K, Fukushima R, Matsubara H, Ohira M, Baba H, Natsugoe S, Kitano S, Takeda K, Yoshida K, Tsunoda T, Nakamura Y. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 2012, 10:141-149. 10.1186/1479-5876-10-141, 3403921, 22776426.
15. Shepherd FA, Douillard JY, Blumenschein GR. Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. J Thorac Oncol 2011, 6:1763-1773. 10.1097/JTO.0b013e31822e28fc, 21876456.
16. Kabaker K, Shell K, Kaufman HL. Vaccines for colorectal cancer and renal cell carcinoma. Cancer J 2011, 17:283-293. 10.1097/PPO.0b013e318232ff44, 21952277.
17. Sienel W, Varwerk C, Linder A, Kaiser D, Teschner M, Delire M, Stamatis G, Passlick B. Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg 2004, 25:131-134. 10.1016/j.ejcts.2003.09.015, 14690745.
18. Shigematsu Y, Hanagiri T, Shiota H, Kuroda K, Baba T, Mizukami M, So T, Ichiki Y, Yasuda M, So T, Takenoyama M, Yasumoto K. Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer. Lung Cancer 2010, 68:105-110. 10.1016/j.lungcan.2009.05.010, 19545928.
19. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006, 24:4721-4730. 10.1200/JCO.2005.05.5335, 16966690.
20. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012, 18:1254-1261.
21. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar M, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597. 10.1200/JCO.2004.08.163, 15117980.
22. Ulahannan SV, Brahmer JR. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest 2011, 29:325-337. 10.3109/07357907.2011.554476, 3082199, 21469981.
23. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl JMed 2003, 349:427-434.
24. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550. 10.1056/NEJMoa061884, 17167137.
25. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009, 27:1227-1234. 10.1200/JCO.2007.14.5466, 19188680.
26. Bubeník J. MHC class I down-regulation: tumour escape from immune surveillance? (review). Int J Oncol 2004, 25:487-491.
27. Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S, Hommura F, Dosaka-Akita H, Nishimura M. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 2007, 98:1424-1430. 10.1111/j.1349-7006.2007.00558.x, 17645781.
28. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420. 10.1158/1078-0432.CCR-09-1624, 19934295.
29. Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Håkansson L, Janetzki S, Kleen TO, Kirkwood JM, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL, Stroncek DF. A systematic approach to biomarker discovery; preamble to " the iSBTc-FDA taskforce on immunotherapy biomarkers" . J Transl Med 2008, 6:81-91. 10.1186/1479-5876-6-81, 2630944, 19105846.
30. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011, 12:1125-1133. 10.1016/S1470-2045(11)70259-5, 22019520.
31. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Takayama T, Yamao K, Uesaka K, Furuse J, Kinoshita T, Nakatsura T. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012, 18:3686-3696. 10.1158/1078-0432.CCR-11-3044, 22577059.
32. Dillman RO, Fogel GB, Cornforth AN, Selvan SR, Schiltz PM, DePriest C. Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines. Cancer Biother Radiopharm 2011, 26:407-415. 10.1089/cbr.2011.0973, 21812653.
33. Lukaszewicz-Zaja{ogonek}c M, Mroczko B, Gryko M, Ke{ogonek}dra B, Szmitkowski M. Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer. Clin Exp Med 2011, 11:89-96. 10.1007/s10238-010-0114-5, 3087107, 20938721.
34. Kwon KA, Kim SH, Oh SY, Lee S, Han JY, Kim KH, Goh RY, Choi HJ, Park KJ, Roh MS, Kim HJ, Kwon HC, Lee JH. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 2010, 10:203-210. 10.1186/1471-2407-10-203, 2886042, 20465852.